-- 史蒂費爾金融集團（Stifel）週四在一份報告中指出，聯準會最近的政策聲明隱含著寬鬆傾向，但隨著政策制定者在利率走向問題上分歧日益加劇，這種傾向可能很快就會消失。 聯邦公開市場委員會（FOMC）週三維持利率不變，這是其連續第三次暫停利率調整。 FOMC表示：「在考慮進一步調整聯邦基金利率目標區間的幅度和時機時，委員會將仔細評估最新數據、不斷變化的經濟前景以及風險平衡。」FOMC 的立場與3月份的立場一致。 史蒂費爾金融集團首席經濟學家林賽·皮耶扎（Lindsey Piegza）寫道，這表明市場仍然傾向於降息。 但這項決定並非一致通過。聯準會理事史蒂芬·米蘭（Stephen Miran）支持降息，而三位官員反對在聲明中加入寬鬆傾向。皮耶札表示，這使得反對者的比例達到了1992年以來的最高水準。 「儘管聯準會目前尚未調整聲明，將寬鬆傾向轉為中性立場，但多位聯準會官員表示支持這樣做，這表明這種調整可能很快就會到來，」皮格札說。 “至少，這些持不同意見的官員向市場和新領導層發出一個信號：許多人認為，目前的數據不支持任何進一步的寬鬆政策，而且，任何試圖實施此類政策的努力都可能面臨強烈的反對。” 週三，參議院銀行委員會將凱文沃什的聯準會主席提名提交給共和黨控制的參議院。沃什是唐納德·川普總統提名的接替傑羅姆·鮑威爾的人選，鮑威爾的聯準會主席任期將於5月15日到期。 鮑威爾表示，他將在卸任主席後繼續擔任聯準會理事。 聯邦公開市場委員會（FOMC）指出，能源價格上漲導致通膨「偏高」。上個月，聯準會將通膨描述為「略微偏高」。
Related Articles
Research
Research Alert: Bio: Q1 Results Above Estimates Despite Meaningful Sales/margin Compression
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:BIO delivered Q1 results showing pressure across both segments, with revenue of $592.1M growing 1.1% Y/Y (~$3M above consensus) but declining 4.2% currency neutral. Adjusted EPS of $1.89 fell 25.6% Y/Y yet beat consensus by $0.10, while operating margin deteriorated 420 bps to 6.6% from 10.8% in the prior year. Both Life Science and Clinical Diagnostics segments experienced currency neutral declines due to ongoing academia weakness and Middle East conflicts. Management lowered 2026 guidance, expecting currency neutral revenue of -3.0% to +0.5% growth (down from +0.5% to +1.5%) and operating margin of 10.0%-12.0% (vs. prior 12.0%-12.5%). Despite operational headwinds, BIO maintained strong cash generation with $78.1M in FCF and repurchased ~176K shares. The company's balance sheet remains healthy, with $1.56B in cash and short-term investments, providing financial flexibility amid challenging market conditions, in our view.
$BIO
Asia
ResMed Posts Higher Fiscal Q3 Non-GAAP Earnings, Revenue
ResMed (ASX:RMD) reported Friday fiscal third-quarter non-GAAP earnings of $2.86 per share, up from $2.37 a year earlier.Analysts polled by FactSet expected earnings of $2.80.Revenue for the three months ended March 31 was $1.43 billion, compared with $1.29 billion a year earlier. Analysts surveyed by FactSet expected $1.42 billion.The company expects its fiscal 2026 non-GAAP gross margin to be between 62% and 63%.The board declared a quarterly dividend of $0.60 per share, up from $0.53 a year earlier, payable June 18 to shareholders on record as of May 14.
$ASX:RMD
Research
Research Alert: Gddy: Strong Profitability Metrics Offset By Continued Revenue Headwinds
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GDDY posted Q1 2026 revenue of $1.2B (+6%), in line with consensus, with EPS of $1.60 beating estimates of $1.52 despite booking deceleration to +2.7% from +5% in Q4. A&C segment growth of +11.6% to $498M showed resilience but continued moderating, while Core Platform remained sluggish at +2.8%. We view booking weakness as concerning given competitive pressures and small business spending constraints that raise questions about growth sustainability. Management reaffirmed 2026 revenue guidance of $5.195B-$5.275B (~6% growth), reflecting limited visibility into booking improvement. However, we see encouraging AI monetization signs with ARPU growth of +9.3% to $246 and Airo AI Builder achieving multi-million dollar annualized bookings within weeks of beta launch. We believe GDDY's impressive margin expansion with NEBITDA margins reaching 32.6% (+210 bps) demonstrates operational discipline, though sustaining A&C growth above 10% remains critical for investor confidence.
$GDDY